Tag Archives: NIH

Woodcock Urges Forward March Toward Personalized Medicine

By Jill Wechsler | Published: May 29, 2013
New approaches for conducting clinical trials and developing therapies that actually prevent and cure disease are key to the future of effective drug therapy, according to Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). Personalized medicine has achieved mainstream status, accounting for more new drug approvals and promising pipeline candidates, [...]
Posted in Technology | Also tagged , , , , , , , , , , | Leave a comment

Budget Cutters Propose Big Hits on Pharma

By Guest Blogger | Published: April 17, 2013
By Jill Wechsler, Washington Correspondent. The Obama administration’s budget plan for fiscal year 2014 apparently assumes that the pharmaceutical industry can support Medicare and other health programs through changes in drug coverage and payments. It also relies on industry fees to keep the Food and Drug Administration up and running. Meanwhile, FDA and other public health [...]
Posted in Guest Blog, Op-Ed, healthcare | Also tagged , , , , , , | Leave a comment

Sequestration: How Big a Hit for FDA, Research and Pharma?

By Jill Wechsler | Published: March 12, 2013
The greatly feared federal budget sequestration mandate went into effect March 1, and, initially, the impact was fairly muted. The stock market soared, employment rose and government workers continued on their jobs. Federal agencies, including the Food and Drug Administration (FDA), launched initiatives to comply with the mandated 5% across-the-board cut in spending (in reality [...]
Posted in FDA, Legal, R&D, healthcare, leadership | Also tagged , , , , , , | Leave a comment

Taxpayers and Embryonic Stem Cell Research

By Ben Comer | Published: August 29, 2012
Last Friday, an appellate court upheld an earlier judgment allowing government to fund embryonic stem cell research for the development of new therapies. Biotechs and advocacy groups cheered the decision but uncertainty remains, in large part due to the possibility of a Romney administration in the White House.
Posted in Biotech, Legal, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , | Leave a comment

Biomedical Innovation in Trouble

By Jill Wechsler | Published: July 27, 2012
The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy makers propose funding cuts for the National Institutes of Health (NIH). This bleak picture of the “state of biomedical innovation” was painted by [...]
Posted in Biotech, FDA, R&D, Technology, healthcare, leadership | Also tagged , , , , | 3 Comments